Biosimilars are bright spot in Hospira's future

12-02-2014 Medill ReportsComments (0)


Indeed, in a global market for so-called biologic drugs estimated at $127 billion annually, Hospira, at last month's “J.P. Morgan Healthcare Conference” in San Francisco, boasted a biosimilar R&D pipeline with a local market value of $40 billion. With ...

Read more on Medill Reports

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top